Exchange: NASDAQ·Updated 01:34 PM EDT
News
all
press releases
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
More News
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion of the acquisition of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine...
Business Wire
Neurocrine's Crenessity Gains Ground in CAH: How Far Can Sales Go?
NBIX's Crenessity gains rapid traction in CAH, with sales soaring and low patient penetration leaving room for growth.
Zacks
If You Invested $100 In Vertex Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.32% on an annualized basis producing an average annual return of 14.56%. Currently, Vertex Pharmaceuticals has a marketread more...
Benzinga
Vertex to Participate in Upcoming September Investor Conferences
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences. Susie Lisa, Senior Vice President of Investor Relations and Manisha Pai, Executive Director of Investor Relations, will participate in a fireside chat at the Wells...
Business Wire
Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock
Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeline progress boost its growth story.
Zacks
Vertex Pharmaceuticals: A Biotech Cash Cow With Pipeline Upside?
Explore the exciting world of Vertex Pharmaceuticals (NASDAQ: VRTX) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!*Stock prices used were...
Nasdaq News: Markets
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead
Key PointsVertex Pharmaceuticals' business could be in trouble if it faces competition in its core market...
Nasdaq News: Markets
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (KSF) are investigating the proposed sale of Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX) to Vertex Pharmaceuticals Incorporated (NasdaqGS: VRTX). Under the terms of the proposed...
Business Wire
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More
Key PointsVertex Pharmaceuticals appears likely to continue to dominate its core therapeutic area...
Nasdaq News: Markets

Advertisement|Remove ads.